Feasibility of central cannabinoid CB1 receptor imaging with [124I]AM281 PET demonstrated in a schizophrenic patient

Psychiatry Research - Neuroimaging

Volumn 147, Issue 2-3, 2006, Pages 249-256

  Berding, Georg ^a   Schneider, Udo ^a   Gielow, Peter ^a   Buchert, Ralph ^b   Donnerstag, Frank ^a   Brandau, Wolfgang ^c   Knapp, Wolfram H ^a   Emrich, Hinderk M ^a   Müller Vahl, Kirsten ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Cannabinoid CB1 receptor; Positron emission tomography; Pyrazole compounds; Schizophrenia

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE I 124; CANNABINOID 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BASAL GANGLION; CASE REPORT; CEREBELLUM; CORPUS STRIATUM; FRONTAL CORTEX; GLOBUS PALLIDUS; GRAY MATTER; HUMAN; ISOTOPE LABELING; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; SCHIZOPHRENIA; TEMPORAL CORTEX; TISSUE DISTRIBUTION; WHITE MATTER;

BRAIN; FEASIBILITY STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MORPHOLINES; POSITRON-EMISSION TOMOGRAPHY; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; SCHIZOPHRENIA;

EID: 33748679326     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pscychresns.2006.02.002     Document Type: Article

References (34)

1. Acton P.D., Pilowsky L.S., Costa D.C., and Ell P.J. Multivariate cluster analysis of dynamic iodine-123 iodobenzamide SPET dopamine D2 receptor images in schizophrenia. European Journal of Nuclear Medicine 24 (1997) 111-118
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text revision (2000), American Psychiatric Press, Washington, DC
3. 9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biological Psychiatry 55 (2004) 904-915
4. Bier D., Dutschka K., Brandau W., and Reiners C. Einfache Synthese von Phenylfettsäure-Tributylzinnverbindungen für schnelle Radioiodierungen mit hohen Markierungsausbeuten am Beispiel der PHIPA 3-10. Nuklearmedizin 37 (1998) A53
5. 123I]epidepride SPET study of amisulpride-treated patients. American Journal of Psychiatry 160 (2003) 1413-1420
6. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103 (2001) 9-15
7. Emrich H.M., Leweke F.M., and Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacology, Biochemistry and Behavior 56 (1997) 803-807
8. 1 receptors in vivo. Journal of Neurochemistry 70 (1998) 417-423
9. Gifford A.N., Makriyannis A., Volkow N.D., and Gatley S.J. In vivo imaging of the brain cannabinoid receptor. Chemistry and Physics of Lipids 121 (2002) 65-72
10. Glass M., Dragunow M., and Faull R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience 77 (1997) 299-318
11. Herkenham M. Cannabinoid receptor localization in brain: relationship to motor and reward systems. Annals of the New York Academy of Sciences 28 (1992) 19-32
12. Herkenham M., Lynn A.B., Little M.D., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America 87 (1990) 1932-1936
13. Hermann H., Marsicano G., and Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109 (2002) 451-460
14. Iversen L. Cannabis and the brain. Brain 126 (2003) 1252-1270
15. Katoch-Rouse R., Pavlova O.A., Caulder T., Hoffman A.F., Mukhin A.G., and Horti A.G. Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity. Journal of Medicinal Chemistry 46 (2003) 642-645
16. Lan R., Gatley S.J., and Makriyannis A. Preparation of iodine-123 labeled AM251: a potential SPECT radioligand for the brain cannabinoid CB1 receptor. Journal of Labelled Compounds and Radiopharmaceuticals 38 (1996) 875-881
17. 1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. The American Association of Pharmaceutical Scientists Journal vol. 1 (3) (1999). http://www.pharmsci.org article 4 (http://www.pharmsci.org)
18. 123I]beta-CIT binding to dopamine transporters in healthy human subjects. Journal of Cerebral Blood Flow and Metabolism 14 (1994) 982-994
19. Leweke F.M., Giuffrida A., Wurster U., Emrich H.M., and Piomelli D. Elevated endogenous cannabinoids in schizophrenia. Neuroreport 10 (1999) 1665-1669
20. 18F]AM5144 and related pyrazole compounds. Nuclear Medicine and Biology 32 (2005) 361-366
21. Logan J., Fowler J.S., Volkow N.D., Wolf A.P., Dewey S.L., Schlyer D.J., MacGregor R.R., Hitzemann R., Bendriem B., Gatley S.J., and Christman D.R. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. Journal of Cerebral Blood Flow and Metabolism 10 (1990) 740-747
22. Logan J., Fowler J.S., Volkow N.D., Ding Y.S., Wang G.J., and Alexoff D.L. A strategy of removing the bias in the graphical analysis method. Journal of Cerebral Blood Flow and Metabolism 21 (2001) 307-320
23. Maes F., Collignon A., Vandermeulen D., Marchal G., and Suetens P. Multimodality image registration by maximization of mutual information. Institute of Electrical and Electronics Engineers (IEEE) Transactions on Medical Imaging 16 (1997) 187-198
24. 18F]SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nuclear Medicine and Biology 27 (2000) 757-762
25. Mathews W.B., Scheffel U., Rauseo P.A., Ravert H.T., Frank R.A., Ellames G.J., Herbert J.M., Barth F., Rinaldi-Carmona M., and Dannals R.F. Carbon-11 labeled radioligands for imaging brain cannabinoid receptors. Nuclear Medicine and Biology 29 (2002) 671-677
26. 123I]omazenil and SPECT. Journal of Neurology, Neurosurgery and Psychiatry 70 (2001) 657-661
27. Reynolds G.P., Czudek C., Bzowej N., and Seeman P. Dopamine receptor asymmetry in schizophrenia. Lancet 1 8539 (1987) 979
28. Rodriguez De Fonseca F., Gorriti M.A., Bilbao A., Escuredo L., Garcia-Segura L.M., Piomelli D., and Navarro M. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: implications for Parkinson's disease and schizophrenia. Neurotoxicity Research 3 (2001) 23-35
29. Scatton B., and Sanger D.J. Pharmacological and molecular targets in the search for novel antipsychotics. Behavioural Pharmacology 11 (2000) 243-256
30. Schmahmann J.D., Doyon J., McDonald D., Holmes C., Lavoie K., Hurwitz A.S., Kabani N., Toga A., Evans A., and Petrides M. Three-dimensional MRI atlas of the human cerebellum in proportional stereotaxic space. Neuroimage 10 (1999) 233-260
31. 123I]iodobenzamide single photon emission computed tomography study. Psychiatry Research: Neuroimaging 75 (1997) 115-123
32. Shirakawa O., Kitamura N., Lin X.H., Hashimoto T., and Maeda K. Abnormal neurochemical asymmetry in the temporal lobe of schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 25 (2001) 867-877
33. Tzourio-Mazoyer N., Landeau B., Papathanassiou D., Crivello F., Etard O., Delcroix N., Mazoyer B., and Joliot M. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 15 (2002) 273-289
34. 3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 28 (2004) 355-360